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Abstract
The importance of maintaining the fidelity of the mitochondrial genome is underscored by
the presence of various repair pathways within this organelle. Presumably, the repair of
mitochondrial DNA would be of particular importance in organisms that possess only a sin-
gle mitochondrion, like the human pathogens Plasmodium falciparum and Toxoplasma gon-
dii. Understanding the machinery that maintains mitochondrial DNA in these parasites is of
particular relevance, as mitochondrial function is a validated and effective target for anti-par-
asitic drugs. We previously determined that the Toxoplasma MutS homolog TgMSH1 local-
izes to the mitochondrion. MutS homologs are key components of the nuclear mismatch
repair system in mammalian cells, and both yeast and plants possess MutS homologs that
localize to the mitochondria where they regulate DNA stability. Here we show that the lack of
TgMSH1 results in accumulation of single nucleotide variations in mitochondrial DNA and a
reduction in mitochondrial DNA content. Additionally, parasites lacking TgMSH1 function
can survive treatment with the cytochrome b inhibitor atovaquone. While the Tgmsh1 knock-
out strain has several missense mutations in cytochrome b, none affect amino acids known
to be determinants of atovaquone sensitivity and atovaquone is still able to inhibit electron
transport in the Tgmsh1 mutants. Furthermore, culture of Tgmsh1 mutant in the presence
atovaquone leads to parasites with enhanced atovaquone resistance and complete shut-
down of respiration. Thus, parasites lacking TgMSH1 overcome the disruption of mitochon-
drial DNA by adapting their physiology allowing them to forgo the need for oxidative
phosphorylation. Consistent with this idea, the Tgmsh1 mutant is resistant to mitochondrial
inhibitors with diverse targets and exhibits reduced ability to grow in the absence of glucose.
This work shows TgMSH1 as critical for the maintenance and fidelity of the mitochondrial
DNA in Toxoplasma, reveals a novel mechanism for atovaquone resistance, and exposes
the physiological plasticity of this important human pathogen.
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Introduction
Toxoplasma gondii is a pervasive obligate intracellular protozoan parasite known to infect
human and all other warm-blooded animals. Infection with Toxoplasma is usually asymp-
tomatic in most healthy individuals as a robust immune response is able to exert pressure
on the rapidly dividing parasites and forcing them into a dormant form, thereby limiting
the tissue destruction caused by the parasite. However, patients with a compromised
immune system, such as transplant recipients receiving immunosuppressant therapies and
patients with AIDS, are at a great risk for developing life-threatening illness as a conse-
quence of the parasite’s unchecked growth [1]. Additionally, infection with the parasite
during pregnancy can cause severe neurological defects or even death of the developing
fetus. First line therapy against acute toxoplasmosis consists of the antifolate pyrimeth-
amine, in combination with sulphadiazine. Nonetheless, these compounds have no effect on
the dormant encysted form of the parasite but there are significant side effects associated
with their use as they can affect the host’s folate synthesis. Considering that approximately
a third of the world’s population is infected with this pathogen and given the significant
patient population with compromised immune systems, infection with Toxoplasma is a seri-
ous public health concern—therefore, the discovery and study of alternative therapies is a
priority [2].
Work on Toxoplasma and other parasites of the phylum Apicomplexa, such as the causative
agent of malaria, Plasmodium falciparum, has pinpointed their single mitochondrion as an
ideal drug target due to its essential function in the parasite’s life cycle and more importantly
its genetic and structural divergence from the host mitochondria [3–5]. Current drugs that are
known to target the mitochondrion of these parasites include atovaquone, myxothiazol, anti-
mycin A and clopidol [6–9]. Of these drugs, atovaquone has been used therapeutically to treat
human pathogens such as, Plasmodium, Toxoplasma, Babesia and Pneumocystis. Co-treatment
with proguanil is often required to mitigate some of the limitations associated with mono-ato-
vaquone treatment, such as bioavailability and resistance [10].
While the importance of Toxoplasma’s mitochondrion for parasite survival and its validity
as a drug target is well established, much of its biology remains to be elucidated. Toxoplasma
has a single mitochondrion, which like that of most protozoa is a double-membraned organ-
elle with tubular rather than plate-like cristae. One major barrier in the study of the mito-
chondrion in Toxoplasma, is the fact that its genome has yet to be fully characterized and
sequenced, primarily due to the presence of fragments of mitochondrial genes inserted into
the nuclear genome [11]. Based on the mitochondrial genomes found in other apicomplex-
ans, such as P. falciparum, the Toxoplasma mitochondrial genome is thought to have three
gene products, cytochrome b (Cyb), cytochrome c oxidase I (Cox1), and cytochrome c oxi-
dase III (Cox3), along with interspersed rRNA elements [12]. Thus, compared to the 13
genes found in the mammalian mitochondrial genome, the apicomplexan mitochondrial
genome is significantly reduced. Nonetheless, the importance of maintaining the function of
the few genes encoded in the apicomplexan mitochondria is underscored by the fact that
inhibition of cytochrome b by atovaquone is lethal to the parasite [9]. However, as of yet, lit-
tle is known about how the mitochondrial DNA of apicomplexan parasites is maintained
and repaired.
As several of the proteins critical for mitochondrial function are encoded within the mito-
chondrial DNA (mtDNA), maintaining its integrity and fidelity is important for cell survival.
While initially it was thought that the mitochondria did not possess DNA damage repair
activity, it is now clear that mtDNA is heavily monitored and modified by multiple repair
pathways. Mechanisms of DNA repair in the mitochondria parallel those present in the
Toxoplasma gondii MSH1 and mitochondrial DNA and function
PLOS ONE | https://doi.org/10.1371/journal.pone.0188040 November 15, 2017 2 / 23
nucleus, including base excision repair (BER), single-strand break repair (SSB), and mis-
match repair (MMR) [13]. Both BER and SSB in the mitochondria are executed by the same
proteins that, as a result of dual localization or alternative splicing, also drive nuclear DNA
repair. By contrast, nuclear MMR proteins are not detected in mammalian mitochondria
[14,15] and genetic disruption of nuclear MMR proteins does not affect mtDNA stability
[16], indicating that the MMR systems in the nucleus and mitochondria are distinct from
each other. In the nucleus, the key components of the MMR machinery are MutS homologue
2 (MSH2), which forms heterodimeric complexes with MutL homolog 1 and either MSH6 or
MSH3. In mammalian mitochondria it has been suggested that the Y-box binding protein,
YB-1, is responsible for recognizing DNA mismatches and, accordingly, its depletion causes
accumulation of mutations in mtDNA [15]. However, the functional partners of YB-1 are
not yet known. By contrast to mammalian cells, yeast possess a MutS homolog, MSH1, that
localizes exclusively to the mitochondria. Importantly, MSH1 disruption results in severe
mtDNA instability [17–19]. Similarly, plants encode for a MSH1 that localizes to the mito-
chondria and regulates substoichimetric shifting [20].
Toxoplasma appears to have full complements of the nuclear BER and SSB factors, however,
it is not known whether these proteins also localize and function in the mitochondrion. As to
mitochondrial MMR, Toxoplasma has a clear MSH1 homolog, TgMSH1 [21], but no clear
equivalent to YB-1. Thus, if mismatch repair occurs in the Toxoplasma mitochondria it is likely
to be more akin to that of yeast and plants rather than mammalian cells. We previously
reported that TgMSH1 localizes to the mitochondrion of Toxoplasma and that its disruption
renders the parasite resistant to the antiparasitic ionophore, monensin, and to the alkylating
agent, methylnitrosourea. This resistance phenotype is directly due to the lack of TgMSH1
rather than a mutator effect, as sensitivity is restored by complementation with a wildtype
copy of the gene. In higher eukaryotes, nuclear mismatch repair enzymes are also known to
directly signal cell cycle arrest and apoptosis in response to cytotoxic levels of DNA damage
[21]. Accordingly, we hypothesized that monensin and other drugs that directly or indirectly
affect the mitochondrion elicit a signaling cascade that is dependent on TgMSH1. Consistent
with this model, we have shown that monensin causes cell cycle arrest and autophagic death in
a TgMSH1 dependent manner [22,23].
However, whether TgMSH1 functions as a bona fide DNA repair enzyme within the mito-
chondrion of Toxoplasma has yet to be explored. MutS and MSH proteins typically contain
five structural domains of which domains I and IV interact with DNA and domain V con-
tains an ATPase and dimerization interface [24,25]. Domains II and III form a connector
domain and the core domain respectively [24,26]. Interestingly, TgMSH-1 contains domains
I and V, but appears to lack domains II, III and IV. While this is an unusual arrangement for
MSHs, the MSH-1 protein in Arabidopsis thaliana (AtMSH-1), which also localizes to the
mitochondria, shares a similar domain organization with TgMSH-1 at the sequence level
[20]. In addition, like AtMSH-1, TgMSH1 includes a C-terminal GIY-YIG endonuclease
domain, which in the protein from A. thaliana is necessary for protein function [21,27].
Within the plant mitochondria, AtMSH-1 is thought to play a role in the suppression of
recombination or amplification of mitochondrial DNA molecules [20]. Thus, given the
sequence and domain arrangement similarities, it is plausible that TgMSH1 has parallel func-
tions in Toxoplasma. Here we show that indeed TgMSH1 is required to maintain the fidelity
and stability of the Toxoplasma mitochondrial genome. Furthermore, we show that the para-
site adapts to the accumulation of mutations within the mitochondrial DNA by reversibly
shutting down mitochondrial function, revealing the metabolic plasticity of this important
human pathogen.
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Results
Strain lacking TgMSH1 function accumulate mutations in mitochondrial
DNA
In yeast, the lack of the MutS homolog Msh1p leads to an increased rate of spontaneous point
mutations in the mitochondrial DNA (mtDNA) [17]. Accordingly, we set out to investigate
whether our Tgmsh1 mutant strain, MRC5, accumulated mutations in its mtDNA during nor-
mal tissue culture maintenance. Using a putative assembly of the Toxoplasma mtDNA (Dr. Jes-
sie Kissinger, personal communication) we designed primers that specifically amplify small
fragments of the mitochondrial genes Cox1 (339 bp), Cox3 (181 bp) and Cyb (176 bp) and that
should be unable to amplify fragments of nuclear DNA (nDNA) (S1 Table and S1 Fig). We
sequenced these fragments from fresh clones established from the parental (WT), the mutant
(MRC5), and complemented (cMRC5) strains, all of which had been maintained in culture for
a prolonged period (approximately 2 years). While the parental clone exhibited no single
nucleotide variations (SNV) in respect to the sequence of each of the genes deduced from the
putative assembly and the genome database, a total of 6 unique SNVs were found within those
fragments from the mutant clones (3 SNVs in clone MRC5a, 4 in MRC5b and 4 in MRC5c,
Fig 1). Interestingly, each the three clones established from the complemented strain had the
same 4 SNVs within the small fragments sequenced (Fig 1A). Since the complemented strain
was generated using the MRC5 mutant strain that had been in culture for approximately 3
months it is possible that those mutations existed prior to the re-introduction of TgMSH1.
This is consistent with the fact that 2 out of the 4 SNVs found in the complimented strains
were also found in the MRC5 clones. To further test this idea, we maintained each of the WT,
mutant and complemented strains for 8 passages (approximately 4 weeks) and re-sequenced
each of the mtDNA fragments. No new SNVs were detected in the WT or any of the three
complemented strains, but in contrast, two new SNVs were detected in MRC5a (Fig 1). Since
after the 8 passages we did not re-clone, we were in effect sequencing from a population and
likely only detecting dominant SNVs. It is important to note that the accumulation of SNVs in
the MRC5 mutant and derived clones appears to be limited to the mtDNA as no variations
were detected in either a 417-base pair fragment of nuclear DNA or a 1128 base pairs fragment
of apicoplast DNA in any of the clones and strains sequenced. Furthermore, the SNVs detected
are not ones seen within the fragments of these genes that are found throughout the nuclear
DNA.
To expand our analysis of mitochondrial DNA we took advantage that the sequence of the
cytochrome b (Cyb) messenger RNA, which is 1,120 bases in length, has been previously deter-
mined and published [28]. Accordingly, we sequenced amplicons of the entire coding region
of cytochrome b from the parental, mutant and complemented strains before (WT, MRC5 and
cMRC5) and after approximately 2 years of constant culture passage (WTmic, MRC5mic and
(cMRC5)mic, where mic stands for “maintained in culture”). While we do not detect any new
SNVs within cytochrome b in either the parental or complemented strains after constant pas-
sage in culture for two years, we detected the emergence of 16 SNVs within cytochrome b in
mutant MRC5 when comparing over the same period of time (Fig 2A and Table 1). Out of the
16 SNVs detected in Cyb in mutant strain MRC5, 8 generate missense mutation and 8 are
silent (Table 1). As we directly sequenced the Cyb amplicon it is not known whether all SNVs
are present simultaneously within the mutant parasites. Nonetheless, these results suggest that
absence of TgMSH1 results in accumulation of mutations in the mitochondrial DNA.
The particular base changes observed in mutated DNA can provide clues as to the type of
DNA damage incurred by the cell. Accordingly, we cataloged and categorized all the SNVs
detected in mtDNA in strains lacking TgMSH1 (Fig 2B). Transitions accounted for the vast
Toxoplasma gondii MSH1 and mitochondrial DNA and function
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majority of substitutions (87%), with 52% of all SNVs being due to AT to GC changes and 35%
due to GC to AT changes (Fig 2B). By contrast, transversions accounted for only 13% of all
mutations detected in the Tgmsh1 mutant strains (AT to TA 3% and AT to CG 10%, Fig 2B).
This is consistent with what has been reported for yeast mitochondria, in which mismatch
repair preferentially corrects transitions, while transversions are corrected through proofread-
ing by the mitochondrial DNA (mtDNA) polymerase [29].
Amount of mitochondrial DNA is affected by lack of TgMSH1
Mitochondrially localized MutS homologs are known to function in maintaining the stability
and integrity of the multi-copy mitochondrial genome in both yeast [17,30] and plants [20].
Accordingly, we investigated whether the copy number of mtDNA was affected in the
Fig 1. Monitoring of mitochondrial DNA in parasites lacking TgMSH1. A. Sequences of three
mitochondrial fragments were monitored in clones of the parental (WT clone a), Tgmsh1 mutant (MRC5
clones a, b and c), and complemented mutant (cMRC5 clones a, b, and c) strains after serial passage in
culture. Horizontal arrows indicate passages in culture; solid ones indicate a known specific number of
passages (psgs), which is indicated above. Black circle represents the establishment of clones of the
particular strain by limiting dilution. The number of single nucleotide variants (SNV) indicated is in respect to
the sequence of the parental strain. B. Schematics depict the emergence and relative position of SNVs in the
MRC5 strain within the three fragments of mtDNA monitored, Cox1, Cox3, and Cyb. Tick marks represent
relative position of SNV.
https://doi.org/10.1371/journal.pone.0188040.g001
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Fig 2. Sequencing of cytochrome b in parental, Tgmsh1 mutant and complemented strain after two
years of culture. A. Total DNA was collected from parental, mutant and complemented strains before (WT,
MRC5 and cMRC5) and after approximately 2 years of constant culture passage (WTmic, MRC5mic and
(cMRC5)mic, where mic stands for “maintained in culture”). The entire coding region of the cytochrome b
gene was amplified and sequenced. The number of single nucleotide variations identified is shown in the gray
boxes below each strain. Arrows represent passage in culture over specified time. Line with black circle,
indicates addition of TgMSH1 to generate the complemented MRC5 strain, cMRC5. B. Distribution of
substitution types in the mitochondrial DNA of the Tgmsh1 mutant strain. All 29 single nucleotide variations
detected in the Cox1, Cox3, and Cyb fragments sequenced (Figs 1 and 2a) were cataloged and categorized
based on the type of substitution.
https://doi.org/10.1371/journal.pone.0188040.g002
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TgMSH1 mutant strain (MRC5) using quantitative PCR (qPCR). To probe for mitochondrial
DNA, we used primers specific to Cox3 and Cyb, and used amplification of nuclear encoded
tubulin to normalize across strains. The assay was validated by comparing nuclear DNA
content across strains using primers against the single copy gene TgCDPK3 [31], which as
expected remained unchanged across all strains tested (Fig 3). By contrast, both mtDNA
fragments assayed were present in less relative amounts in the initial MRC5 mutant strain
and the same strain maintained in constant culture for approximately 2 years (Fig 3). Impor-
tantly, we noted that the relative amount of mtDNA decreases as the mutant strain is main-
tained in culture for prolonged periods of time, regardless of whether we probed for Cox3 or
Cyb (Fig 3). In the case of Cox3, for instance, the mtDNA amount is 72% of that in parental
for the low passage MRC5 strain but drops to 30% of parental for the same strain after two
years of passage. Thus, TgMSH1 appears to be critical for maintenance of the mitochondrial
genome in Toxoplasma.
Parasites lacking TgMSH1 function are tolerant to atovaquone treatment
Resistance to atovaquone in both Toxoplasma and P. falciparum is associated with point muta-
tions in cytochrome B that prevent atovaquone from binding to the active site [28]. None of
the mtDNA mutations we identified in the Cyb of the MRC5 mutant matched previously char-
acterized point mutations linked to atovaquone resistance in Toxoplasma or P. falciparum
[11,14–16]. Nonetheless, as we sequenced PCR fragments from uncloned parasites, it is plausi-
ble that some parasites within the culture of the Tgmsh1 mutant strain carry mutations that
could impart atovaquone resistance. To investigate this possibility, we seeded 106 parasites of
the parental or MRC5 strain into tissue culture flasks containing confluent human foreskin
fibroblasts (HFFs, approximate multiplicity of infection of 0.2), in the presence of 3μM atova-
quone. After five days, the flasks were fixed and stained with crystal violet to visualize plaques,
which are clearings of the cell monolayer resulting from dividing parasites. While no plaques
were detected in the flask containing parental parasites, we counted approximately 100 plaques
in the flask seeded with the MRC5 mutant strain. Nonetheless, these plaques were much
Table 1.
Nucleotide Protein MRC5mic cMRC5 cMRC5mic Nucleotide Protein MRC5mic cMRC5 cMRC5mic
A103G I35V x T651G C217W x
G154A A52T x A659G Y220C x
G168A n.c. x x T701C M234T x x
T207C n.c. x C757T H253Y* x
A228G n.c. x x A758G H253R* x
A286G n.c. x x A771G n.c. x
G346A A116T x A786G n.c. x
T399C n.c. x A846G n.c. x
A567G n.c. x T891C n.c. x
G586A A196T x x x T901C n.c. x
List of nucleotide variations found within cytochrome b in the MCRC5 strain maintained in culture for prolonged time (MRC5mic), the complemented MRC5
strain (cMRC5), and the complemented strain maintained in culture (cMRC5mic). Generation of the various strains listed is illustrated in Fig 2. Nucleotide
and amino acid numbers are based on the published cytochrome b sequence [28]. Marks (x) indicate variation is found in the particular strain listed on top of
column. n.c. (no change) indicates the variation causes a silent mutation.
*If nucleotide mutation is CA757-758TG protein change is H253C.
https://doi.org/10.1371/journal.pone.0188040.t001
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smaller in size than those formed by untreated parasites after five days. Furthermore, inspec-
tion at high magnification revealed a multitude of clusters of vacuoles that had not formed pla-
ques but appeared to be viable. By contrast, neither plaques nor normal looking vacuoles were
detected in the culture of 106 atovaquone-treated parental strain parasites. This phenomenon
suggested that all or a vast majority of MRC5 parasites added to the culture were surviving ato-
vaquone treatment, but with a slow growth rate. To quantify this observation, we inoculated
HFFs grown in 12-well tissue culture plates with 500 parasites of either the parental, MRC5, or
complemented strain and allowed the parasites to grow in varying concentrations of atova-
quone until plaques were detected. No plaques were detectable in any of the drug treated cul-
tures at either 5 or 7 days, at which time-points large plaques are clearly visible in untreated
parasites. Nonetheless, plaques were clearly visible for the mutant strain in the presence of ato-
vaquone at 12 days. Accordingly, we fixed cultures at 12 days and enumerated plaques to com-
pare survival among strains. In the presence of atovaquone we saw increased survival in the
MRC5 mutant as compared to the parental or the complemented strains. At the highest con-
centration of atovaquone (3μM) 65% of the parasites survived while only 15% of the parental
had survived (Fig 4). Interestingly, we only saw a partial rescue of the atovaquone sensitivity in
the complemented strain (33% at 3μM), suggesting that the tolerance to atovaquone in the
mutant strain could be due to irreversible events that had occurred prior to the addition of the
wildtype copy of the gene.
It is plausible that during our 12-day assay to test atovaquone sensitivity, SNVs that would
give rise to atovaquone resistance had emerged, and that in effect our assay artificially
Fig 3. Quantification of mitochondrial DNA in parental and mutant strains. Quantitative PCR analysis
was performed on genomic DNA obtained from parental, Tgmsh1 mutant (MRC5) and Tgmsh1 maintained in
constant culture (MRC5mic). Bar graph represents the relative copy number of Cox1, Cyb and CDPK3
(nuclear control) present in each strain as compared to the parental strain. Total DNA content was normalized
using the Toxoplasma alpha tubulin gene as a control. Graph represents three biological replicates; error bars
are the standard deviation. Asterisks denote statistically different from parental based on one-way ANOVA
followed by post-hoc Tukey HSD test (p<0.01). Pound sign denotes that MRC5mic is statistically different
from MRC5 based on the same analysis (p<0.01).
https://doi.org/10.1371/journal.pone.0188040.g003
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selected for atovaquone resistant mutants. This is highly unlikely, given that we see close to
100% survival at lethal concentrations, meaning that resistance would have had to develop
within each of the plaques. Nonetheless, we tested this possibility by collecting parasites after
12 days of growth in 3μM atovaquone and testing their sensitivity to atovaquone through
plaque assays (S2 Fig). We noted no difference in atovaquone sensitivity between the mutant
parasites before and after the 12 days of growth in atovaquone. Thus, the ability of MRC5
parasites to survive atovaquone treatment is not due to an artificial selection within the 12
days of the assay.
TgMSH1 mutant strain remains sensitive to inhibition of electron
transport by atovaquone
The fact that we observe nearly 100% survival of the mutant strain at 1.5, 2.0 and 2.5 μM atova-
quone (100%, 96%, 84%, and 67% respectively), all concentrations to which the parental strain
shows sensitivity, would indicate that all of the mutant parasites that were added to the culture
were already resistant to the drug. Atovaquone inhibits respiration but resistant strains are
known to respire in the presence of the drug [6,32,33]. Accordingly, to test whether the MSH1
mutant strain was resistant to the effects of atovaquone on respiration, we tested oxygen con-
sumption using commercially available oxygen detection plates. Specifically, parasites were
added to a well of an OxoPlate (PreSens) containing an artificial intracellular salt solution
buffer (AISS) and either vehicle control or atovaquone (1.5μM or 3.0μM). Changes in oxygen
saturation were measured every ten minutes over a period of two hours at 37˚C (Fig 5). As
expected, both the wildtype and MRC5 mutant strains consumed oxygen in the presence of
Fig 4. Sensitivity to atovaquone treatment. Parasites of wildtype, MRC5 mutant, or MRC5 complemented
strains were allowed to form plaques in media containing atovaquone or solvent control. Percent survival
represents the number of plaques formed in the presence of atovaquone after 12 days of growth divided by
the number of plaques formed in the presence of solvent control. Data bars represent the average of four
independent experiments, and error bars denote the standard deviation. Asterisks denote statistically different
from parental based on one-way ANOVA followed by post-hoc Tukey HSD test (* p<0.05, ** p<0.01). Pound
sign denotes that cMRC5 is statistically different from MRC5 based on the same analysis (#p<0.05).
https://doi.org/10.1371/journal.pone.0188040.g004
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DMSO which was used as the solvent. Interestingly, however, respiration was inhibited in both
the wildtype and the MRC5 mutant in the presence of atovaquone (Fig 5A). This would sug-
gest that atovaquone was still able to inhibit respiration in MRC5 mutant, although they are
able to survive prolonged atovaquone treatment in culture. To validate our approach, we mea-
sured the respiration of the atovaquone resistant parasite line, R5Q5, which contains a specific
mutation in CYB that prevents atovaquone binding to the Qo pocket, alongside it’s parental
strain, PDS [28]. As predicted, R5Q5 continues to consume oxygen at 1.5μM, while it’s paren-
tal, PDS, does not (Fig 5B). It is important to note that the atovaquone IC50 for the PDS strain
is 0.05uM, which is significantly lower than that for the RH derived strains, such as MRC5
[28]. These results confirm that the cytochrome b mutations found in the MRC5 mutant are
Fig 5. Effect of atovaquone treatment on respiration in the Tgmsh1 mutant strain. Fifty millions of
freshly harvested parental or Tgmsh1 (MRC5) mutant parasites were added to Oxoplate (PreSens) wells
containing artificial intracellular salt solution (AISS) buffer and drug for a final concentration of 1.5μM
atovaquone (dashed line), 3.0μM atovaquone (dotted line) or DMSO vehicle control (solid line). Fluorescence
readings at 540nm/650nm (indicator) and 540nm/590nm (reference) were measured every 10 minutes over
the course of two hours at 37˚C. Percent oxygen concentrations were calculated using the fluorescent
readings obtained from each sample well and control wells (100% oxygen saturated solution or oxygen
depleted solution) and then normalized to the internal reference fluorescence for each well. A representative
graph of three biological replicates is shown, each data point is an average of at least three experimental
repeats. B. The same experiment as described above was performed using the previously characterized
atovaquone resistant strain R5Q5 [9] and its parental strain PDS.
https://doi.org/10.1371/journal.pone.0188040.g005
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not blocking atovaquone binding to its active site and that the ability of the mutant to grow in
atovaquone is due to a novel mechanism.
TgMSH1 mutant strain shows tolerance to other mitochondrial function
inhibitors
Resistance to atovaquone despite of effective inhibition of electron transport, as we see with
our mutant, is reminiscent to what has been reported for the P. falciparum drug selected strain
SB1-A6 [34]. Interestingly, SB1-A6 does not have mutations in cyb and is resistant not only to
atovaquone but also to other cyt bc1 inhibitors such as stigmatellin, myxothiazol, antimycin A,
clopidol, and WR243251 [34]. Accordingly, we tested whether Toxoplasma mutant strain
MRC5 was also resistant or tolerant to three other electron transfer inhibitors: myxothiazol,
clopidol, and antimycin A (Fig 6). Similar to what was noted with atovaquone, no obvious pla-
ques were seen after 5 days of culture in presence of lethal doses of any of these three drugs
with either the parental or mutant strain. Nonetheless, by 12 days of drug treatment we noted
significant differences in sensitivity, with mutant MRC5 exhibiting high level of survival at
normally lethal concentrations of myxothiazol, clopidol and antimycin A (Fig 6A–6C). For the
MRC5 mutant we detect 57% survival at 100 μg/ml clopidol (vs 3% for parental strain), 58% at
20 μM antimycin A (vs 2% for parental), and 67% at 33 ng/ml myxothiazol (vs 4% for paren-
tal). Importantly, this multidrug tolerance appears to be specific to inhibitors of mitochondrial
function as we do not see any differences between the strains in sensitivity to pyrimethamine,
which inhibits dihydrofolate reductase [35–37], or clindamycin, which targets Toxoplasma’s
apicoplast by binding to its ribosomal RNA [38], regardless of how long we incubate the para-
sites in the drug (Fig 6D and 6E).
Growth of TgMSH1 mutant in atovaquone gives rise to strains with high
level of drug resistance
Although we did not detect mutations that have been previously associated with atovaquone
resistance in the TgMSH1 knockout strain, we hypothesize that, given its mutator pheno-
type, under the right pressure those mutations could emerge. Accordingly, we grew parental,
MRC5 mutant and complemented parasites in continuous passage under the presence of
2.5μM atovaquone. Neither the parental or complemented parasites survived the treatment
beyond three passages in three independent attempts, however the MRC5 mutant parasites
were successfully maintained in atovaquone for approximately 30 passages, at which point
we began seeing robust growth in the presence of the drug. The surviving parasites popula-
tion were cloned through limiting dilution. To confirm and quantify the observed resistance
we tested the ability of parasites to form plaques after 5 days of growth in the presence of ato-
vaquone (Fig 7A). As expected, no plaques were detected in the parental or the original
MRC5 mutant, however we see significant survival in the Atovaquone-selected MRC5
mutant (MRC5-AtoSel). At 3μM atovaquone we observe 86% (±2.87%) survival for the
MRC5-AtoSel clone, while no plaques were detected in neither the parental nor the original
MRC5 mutant at the same concentration (Fig 7A). Thus, continuous growth in atovaquone
enhanced the ability of MRC5 to grow in atovaquone, suggesting the development of true
resistance to the drug. To determine if the resistance was due to a mutation in Cyb we
sequenced the gene and detected two new missense mutations in comparison to the MRC5
strain: R70K and A116V. Nonetheless, the affected amino acids have not been previously
implicated with resistance and are not part of the atovaquone binding pocket, suggesting
that there is an alternative atovaquone site in Cyb or, more likely, that the resistance pheno-
type could be due to a Cyb independent mechanism.
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Atovaquone selected mutants have significantly reduced respiration and
are dependent on glucose
To explore the mechanism of resistance of the MRC5-AtoSel clone, we tested its ability to con-
sume oxygen in the presence of atovaquone. Interestingly, we detected reduced oxygen con-
sumption in these parasites in the absence of the inhibitor (Fig 7B). While we maintain the
MRC5-AtoSel strain in atovaquone, parasites were grown in the absence of drug for 36 hours
prior to the oxygen consumption assay. Thus, the lack of respiration is not likely due to a
Fig 6. Sensitivity of Tgmsh1 mutant strain to mitochondrial inhibitors. Parasites of the parental and
MRC5 mutant strains were allowed to form plaques in presence of varying concentrations of myxothiazol (A),
clopidol (B), antimycin A (C), pyrimethamine (D), or clindamycin (E). Percent survival represents the number
of plaques formed in the presence of drug after 12 days of growth divided by the number of plaques formed in
the presence of solvent. Data bars represent the average of three independent experiments, and error bars
denote the standard deviation. Asterisks indicates significant statistical difference based on one-way ANOVA
(*p<0.05, **p<0.005).
https://doi.org/10.1371/journal.pone.0188040.g006
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Fig 7. Characterization of Tgmsh1 mutant parasites after selection in atovaquone. A. Intracellular
MRC5 mutant parasites and MRC5 parasites selected for growth in atovaquone (MRC5-AtovSel) were
allowed to form plaques in media containing atovaquone or solvent control. Percent survival represents the
number of plaques formed in the presence of atovaquone after 5 days of growth as compared to the number
of plaques formed in solvent control. Data bars represent the average of three independent experiments, and
error bars denote the standard deviation. B. The ability of MRC5 (dashed line) and MRC5-AtoSel (solid line)
parasites to consume oxygen under standard conditions was measured every 10 minutes over 120 minutes,
as for Fig 5. Curves are average of triplicate data points. C. Parental, MRC5, and MRC5-AtoSel parasites
Toxoplasma gondii MSH1 and mitochondrial DNA and function
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residual effect from the drug. Regardless, it appears that the MRC5-AtoSel strain can grow
effectively despite a significant reduction respiration rate.
Given the reduced cellular respiration activity of the atovaquone-selected parasites, it
would follow that these parasites are dependent on glycolysis as their primary source of cellular
energy. To explore this possibility we grew parental, Tgmsh1 mutant strain (MRC5), and
MRC5-AtoSel parasites in media containing either 0 or 25 mM glucose (the amount present in
the normal growth media used for parasite maintenance). Parasites of the parental strain
exhibited the same level of growth with or without glucose (Fig 7C). By contrast, the MRC5-A-
toSel parasites exhibited an approximately 80% reduction of growth in media lacking glucose
as compared to normal media (Fig 7C). This indicates that this parasite strain is dependent on
glycolysis due to impaired or inhibited mitochondrial function. Interestingly, the original
MRC5 strain also exhibited reduced growth in the absence of glucose, albeit to a lesser extent
than the atovaquone selected clone (Fig 7C).
Atovaquone resistance reverts when selection pressure is removed
Interested in determining if the atovaquone resistance phenotype is stable, we removed the
atovaquone selection pressure for approximately 30 passages (~3 months) and tested atova-
quone sensitivity in comparison to the other strains. The atovaquone selected parasites, which
were maintained in the presence of the inhibitor, continue to exhibit survival in atovaquone
(Fig 8A). However, the MRC5AtoSel parasites for which selective pressure was removed (aka
MRC5AtoSel w/o ato) were unable to form plaques following five days in the presence of ato-
vaquone (Fig 8A). Thus, the apparent resistance to atovaquone of the MRC5AtoSel parasites is
not stable and therefore unlikely to have a genetic basis. Additionally, we performed respira-
tion assays with the MRC5 parasites, both atovaquone-selected clones, and the reverted para-
sites. Interestingly, while the atovaquone selected parasites have reduced respiration as noted
before, the reverted parasites consume oxygen at higher rate (Fig 8B).
Discussion
The requirement for monitoring and maintaining the fidelity of DNA in the mitochondria is
underscored by the presence of various repair pathways within this organelle. Presumably,
repair of errors or damage in mitochondrial DNA would be of particular importance in organ-
isms that possess only a single mitochondrion, like the human pathogens, Plasmodium falcipa-
rum and Toxoplasma gondii. Surprisingly, very little is known about the proteins and pathways
involved in maintaining and repairing mitochondrial DNA (mtDNA) in apicomplexan para-
sites. We have shown that genetic disruption of a MutS homolog protein in Toxoplasma
(TgMSH1) leads to the accumulation of nucleotide variations in the mtDNA and loss of
mtDNA. The functions of the Toxoplasma TgMSH1 described here, parallel those of plant and
yeast MSH1. In addition, we noted that parasites lacking TgMSH1 have tolerance to diverse
inhibitors of mitochondrial electron transfer and can adapt to growth in atovaquone, a potent
cytochrome b inhibitor.
were allowed to grow in either 0mM or 25mM glucose (normal culturing conditions) for five days. Level of
parasite growth was determined based on β-galactosidase activity by reading absorbance at 24 hours
following the addition of the substrate CPRG. For each strain, the growth rate in 0mM glucose was
determined by dividing the measured absorbance level in 0mM glucose by that detected in 25mM glucose.
Asterisk denotes statistically different from parental based on one-way ANOVA followed by post-hoc Tukey
HSD Test (* p<0.01). Pound sign denotes that MRC5-AtoSel is statistically different from MRC5 based on the
same analysis (# p<0.05).
https://doi.org/10.1371/journal.pone.0188040.g007
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The nuclear encoded MutS homolog from Saccharomyces cerevisiae, ScMSH1, which pref-
erentially binds to DNA mismatches and unpaired nucleotides in vitro, also localizes solely
to the mitochondria [19]. Genetic disruption of yeast MSH1 results in the accumulation of
point mutations in mitochondrial DNA [19] and instability of mtDNA [17,39]. Interestingly,
Fig 8. Atovaquone sensitivity of MRC5-AtovSel parasites maintained with and without atovaquone. A.
The efficiency of plaque formation in atovaquone within five days was determined for MRC5 atovaquone
selected parasites that were maintained in atovaquone (MRC5-AtovSel) and those that were maintained in
the absence of atovaquone after the selection (MRC5-AtovSelRev). Percent survival represents the number
of plaques formed in the presence of atovaquone after 5 days of growth divided by the number of plaques
formed in the presence of solvent control, multiplied by 100. Data bars represent the average of three
independent experiments, and error bars denote the standard deviation. B. The ability of MRC5 (dashed line),
MRC5-AtoSel (solid line) and MRC5-AtovSelRev (dotted line) parasites to consume oxygen under standard
conditions was measured every 10 minutes over 120 minutes as for Fig 6.
https://doi.org/10.1371/journal.pone.0188040.g008
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analysis of different yeast MSH1 mutants indicate that besides mismatch repair, this protein
might be involved in recombination surveillance and heteroduplex rejection [30]. Further-
more, it has been proposed that ScMSH1 plays several roles in mitochondrial base excision
repair [40]. A similar role in mitochondrial DNA stability and organization has also been
ascribed to the plant MSH1. Plant MSH1 regulates substoichiometric shifting [20,41], a phe-
nomenon of that can produce novel subgenomic DNA molecules [42,43]. Thus, the two
phenotypes observed with our TgMSH1 mutant strain, accumulation of single nucleotide
mutations and loss of signal from PCR of mitochondrial DNA, are consistent with the func-
tions of mitochondrial MutS homologs.
Whether Toxoplasma mitochondrial DNA undergoes substiochiometric shifting is not
known, although it is plausible giving the parallels between the MSH1 from plants and Toxo-
plasma. In addition to the domains found in all eukaryotic MutS homologs, the plant MSH1
contains a GIY-YIG homing endonuclease not found in MutS homologs from yeast and mam-
malian cells [27]. Interestingly, MSH1 from Toxoplasma and related parasites of the phylum
Apicomplexa contain this endonuclease domain. Nonetheless, detection of any possible
restructuring of Toxoplasma’s mitochondrial DNA is complicated by the fact that its sequence
and structure has not been completely deciphered. On the other hand, the mitochondrial
DNA has been well characterized in various Plasmodium species and determined to be a 6 kb
unit with tandemly arranged repeating sequences [44–50]. For Plasmodium parasites, the
mitochondrial genome appears to be a multi-copy element with an estimated 150 per cell in P.
yoelii [46] and 15 to 10 in P. gallinaceum [51]. Thus, it is likely that the mitochondrial DNA of
Toxoplasma is multi-copy and composed of repeating elements. Indeed, our data shows vari-
ability in the amount of DNA detected for several fragments of mtDNA between strains (Fig
3). This result would indicate that the mitochondrial DNA is either multi-copy or repetitive
and that TgMSH1 is required for its maintenance. At this point we do not know whether the
reduction in quantitative PCR signal for mtDNA fragments in MRC5 is due to a loss of copies
of a presumably multi-copy genome or recombination and rearrangements within the existing
genomes.
Both loss of genetic material and accumulation of single nucleotide mutations would be pre-
dicted to affect mitochondrial function if either were to affect the expression levels or sequence
of the mitochondrially encoded proteins. Interestingly, the Tgmsh1 mutant strain MRC5
exhibits reduced ability to grow in the absence of glucose, which would suggest an impairment
of mitochondrial function as it relates to ATP production. As parasites lacking TgMSH1 do
not exhibit a significant reduction in propagation efficiency under normal culture conditions
[21], it would appear that the mutant parasites can adapt to compromised mitochondrial func-
tion. This adaptation might account for the mutant’s ability to grow in the presence of atova-
quone. Atovaquone, a naphthoquinone, functions as a competitive inhibitor of the Qo site in
complex III (cytochrome bc1) preventing ubiquinol (QH2) from completing the Q cycle and
ultimately disrupting the electron flux through the rest of the electron transport chain. Atova-
quone resistance in both Toxoplasma and Plasmodium spp. have been attributed to cytochrome
b mutations that disrupt atovaquone binding to the Qo pocket [9,33]. Nonetheless, none of the
missense mutations that we detect within Cyb in our mutant strains are in amino acids associ-
ated with resistance [6,9,33,52–54] or that are known to come in contact with atovaquone [55].
Accordingly, the mutant parasites remain sensitive to the effects of atovaquone on respiration
despite their ability to grow in presence of the drug. Thus, it is likely that the ability of the
mutant to survive atovaquone treatment is not directly due to the mutations in Cyb, but rather
a consequence of a generalized adaptation to the loss of mitochondrial function.
The idea that the Tgmsh1 mutant has adapted to disrupted mitochondrial function is sup-
ported by data showing that the mutant strain can survive not only in the presence of
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atovaquone, but also in myxothiazol, antimycin A and clopidol. Like atovaquone, myxothiazol
targets the cytochrome bc1 complex by binding to the Qo site in cytochrome b, but likely
within distinct binding regions. On the other hand, antimycin A targets the quinone reductase
(Qi) site [56,57] while the target site for clopidol is less characterized [58]. The fact that the
mutant parasite is resistant or tolerant to these distinct inhibitors further points to an alterna-
tive mechanism of resistance. Possible scenarios include a shift in metabolism that allows the
parasites to survive inhibition of the electron transport chain, albeit at a lower replication rate,
or an ability by the mutant parasite to remain quiescent until the drug concentration in the
media is reduced by turn over. Attempts to differentiate between these two possibilities proved
to be inconclusive. Nonetheless, we were able to obtain parasites that replicated robustly in
atovaquone by continuous passage of the mutant strain in presence of the drug. These adapted
strains remained sensitive to atovaquone in terms of inhibition of respiration and were more
dependent on glucose than the original MRC5 mutants. The increased dependence on glucose
for parasite growth would suggest that the Tgmsh1 mutant strain had already begun shifting
towards glycolysis as the primary source of energy, while the atovaquone selected parasites
shifted even further to favor glycolysis. Interestingly, this enhanced tolerance to atovaquone is
reversible, which underscores that it is not due to a genetic mutation. Thus, we hypothesize
that, to overcome the disruption of mitochondrial DNA, the parasites lacking TgMSH1 have
adapted their physiology as to survive with a functionally compromised mitochondrion.
Interestingly, tolerance to diverse cyt bc1 complex inhibitors has been reported for P. falcip-
arum strain SB1-A6. This strain was generated by culturing parasites in the presence of 3-
(6,6,6-trifluorohexyloxy)-6-amino-acridone (6-NH2 Ac), a potent inhibitor of P. falciparum
that is postulated to target cyt b [34,59]. Like our Tgmsh1 mutant, SB1-A6 can grow in the pres-
ence of atovaquone, myxothiazol and antimycin A, even though these drugs effectively inhibit
the electron transport chain [34]. Importantly, no mutations are present in the Cyb sequence
of SB1-A6 suggesting a biochemical adaptation that allows the strain to bypass the need for
conventional electron transport. It has been proposed that in Plasmodium spp. electron trans-
port is not critical for energy production and that instead it is essential for de novo pyrimidine
synthesis via dihydroorotate dehydrogenase (DHODH) [60]. This is unlikely to be the case for
Toxoplasma, in which atovaquone inhibits mitochondrial function but does not affect pyrimi-
dine biosynthesis [61]. Nonetheless, the fact that both Toxoplasma and Plasmodium can adapt
as to survive the inhibition of mitochondrial function indicates a remarkable ability by these
parasites to adapt their physiology. Whether the mechanisms responsible for such adaptation
are the same in both Plasmodium and Toxoplasma is not currently known and would necessi-
tate a more in-depth analysis of the metabolism and physiology of the mutant strains.
The analysis of our Toxoplasma mutant strain, MRC5, has revealed TgMSH1 as critical for
the maintenance and fidelity of the mitochondrial DNA. Given how little is known about
Toxoplasma’s mitochondrial genome, the identification of a protein that associates and acts on
mitochondrial DNA could open the door to a more complete understanding of the apicom-
plexan mitochondrion. Future work would focus on dissecting the contribution of the various
domains found in TgMSH1 to its function in DNA repair and identification of protein interac-
tors. Furthermore, our results provide important information about atovaquone, showing that
resistance to this clinically relevant drug can occur through mechanisms independent of muta-
tions in the binding site of its target protein Cyb. Toxoplasma, like Plasmodium, appears to
have the ability to forgo the need of the electron transport chain and adapt its biochemistry to
survive treatment with diverse mitochondrial inhibitors. Understanding the mechanism
behind this adaptation will undoubtedly reveal novel information about the physiology of this
important human pathogen, which could educate the development of new treatments and
avoid the development of drug resistance.
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Materials and methods
Ethics statement
No animals or human subjects were used in this study.
Parasite and host cell maintenance
For the experiments described here, we used MRC5 parasite line previously characterized [21]
and its parental strain, RHΔhpt+GFP+βgal, which expresses GFP and β-galactosidase (βgal)
[62]. Toxoplasma tachyzoites were propagated by passaging in human foreskin fibroblasts
(HFFs, purchased from the American Tissue Culture Collection, ATCC) in a humidified
incubator maintained at a temperature of 37˚C and 5% CO2 concentration. Normal growth
medium used was Dulbecco’s Modified Eagle Medium (Life Technologies) supplemented with
10% fetal bovine serum (Atlanta Biologicals), 2 mM L-gluatamine (Life Technologies) and
50 μg/mL penicillin-streptomycin (Life Technologies). Atovaquone was purchased from
Sigma-Aldrich and prepared using DMSO as solvent.
Sequencing of mitochondrial, nuclear and apicoplast DNA fragments
Total genomic DNA was isolated from freshly lysed out parasites using the DNeasy blood and
tissue kit (Qiagen). Fragments of Cox1, Cox3, and Cyb, nuclear, and apicoplast DNA, were
amplified using Phusion high fidelity polymerase and primers 1 to 10 listed in S1 Table (S1
Table). Full length Cyb was amplified using primers 11 and 12. Resulting DNA fragments were
purified using gel or column purification kits from Qiagen, and submitted for sequencing at
ACGT, INC (Wheeling, IL).
Quantification mitochondrial DNA copy number
Total DNA was collected from freshly egressed parasites using the DNeasy blood and tissue kit
(Qiagen). The mtDNA copy number was determined by real-time polymerase chain reaction
using primers 3 and 4 for Cox3 and 5 and 6 for Cyb (S1 Table) and following manufacturer’s
instructions for the Fast SYBR Green Master Mix (Applied Biosystems, Thermo Fisher Scien-
tific, Vilnius, Lithuania). As control for nuclear DNA we used primers 13 and 14 for CDPK3
(S1 Table). The quantity of DNA was normalized to the expression of the nuclear Toxoplasma
alpha tubulin (TUBA1) gene using primers 15 and 16 (S1 Table). The baseline and threshold
(Ct) was determined by the Sequence Detection System software imbedded into the Applied
Biosystems program and verified manually. The relative amount of mtDNA was calculated
using the ΔΔCt method. Specifically: ΔΔCt = ΔCT(target sample) − ΔCT(parental); where ΔCT =
CT(target gene)−CT(TUBA1). Finally, the relative DNA amount was expressed as 2ΔΔCT.
Quantification of drug resistance
Drug resistance was quantified by assessing each strain’s ability to form plaques in the presence
of the drug tested. Five hundred parasites of each strain were added to HFFs grown to con-
fluency in normal culture conditions in 12 well tissue culture plates. Following a 4–5 hours
incubation period, media and uninvaded parasites were aspirated and media containing the
drug at various concentrations were added to the wells. For the no drug control, we used
DMSO, or appropriate solvent, at the highest amount used. Parasites were incubated under
these conditions until plaques formed, after which the cultures were fixed with 100% metha-
nol, stained with crystal violet, and plaques were counted using a stereomicroscope. The per-
cent survival, based on the ability of parasites to form plaques, was calculated as the number of
plaques formed in drug divided by the number of plaques formed in vehicle control, and
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multiplied by 100. Statistical significance was tested using one-way Anova followed by post-
hoc Tukey HSD test as well as Bonderroni and Holm multiple comparison using Prism.
Oxygen consumption assays
To measure parasite respiration, we used OxoPlate (OP96F) from PreSens according to the
manufacturer’s instructions. In brief, intracellular parasites were passed through a syringe, fil-
tered through a 3 μM to eliminate host cell debris, and resuspended at 5 x 108 p/ml in an artifi-
cial intracellular salt solution (AISS) [63]. A total of 5 x 107 parasites were added to each well
containing either vehicle control or atovaquone at 2x (2.0μM or 6.0μM) in AISS buffer.
Changes in oxygen saturation were measured every ten minutes over a period of two hours at
37˚C using a Biotek Synergy H1 fluorescence plate reader set at 540/650 nm (indicator) and
540/590 nm (reference); integration time: 0 to 500μs and gain 50. Wells containing fully satu-
rated water or oxygen depleted water (with sodium sulfite) were used for calibration. Calcula-
tions to determine the percent oxygen saturation in the well were carried out as outlined in the
manual.
Generation of MRC5AtoSelected and reverted parasites
Parental and MRC5 parasite clones were subjected to growth under 2.5μM atovaquone for 50
passages. As a control, the same clone was maintained without drug alongside the drug-
selected strain. After 30 passages, the MRC5AtoSel parasite population was cloned out under
limiting dilution. To obtain the reverted strain the atovaquone selection pressure was removed
for 30 passages.
Measuring parasite growth in no glucose conditions
Intracellular parasites were freed from cells by passing through a syringe after which they were
passed through a 3μM filter to eliminate host cell debris and resuspended in complete DMEM
media lacking phenol red to a concentration of 1000 parasites/ml. 100 parasites of each strain
were added to HFFs grown in 96-well plates in phenol red free media. The parasites were
allowed to invade for 2–3 hours in the presence of glucose, after which, the media was removed
and the wells were washed twice with no glucose media. Finally, the wells were filled with phe-
nol-red free media containing either 0 or 25mM glucose and the parasites were allowed to
grow for five days under standard parasite growth conditions. Approximately 24 hours prior
to measurements, Chlorophenol red-β-D-galactopyranoside, (CPRG, Sigma) was added to a
final concentration of 100 μM [64]. Endpoint absorbance measurements were taken at 540 nM
wavelength using a Synergy H1 Plate Reader. Control values from wells containing uninfected
cells were obtained and subtracted from the experimental absorbance measurements. Finally,
the corrected absorbance values were normalized by dividing by the values of parasites grown
in normal glucose (25 mM). The experiment was repeated for a total of three times statistical
significance was tested as described above for quantification of drug resistance.
Supporting information
S1 Fig. Sequence of mitochondrial DNA fragments. Shown are the sequences of PCR frag-
ments used to monitor Cox I, Cox III and Cyb in parental and mutant strains. Underlined
regions indicate primers used to amplify fragments. Highlighted bases are ones found to be
mutated in the Tgmsh1 mutant parasites.
(PDF)
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S2 Fig. Atovaquone sensitivity of MRC5 parasites grown in atovaquone for 12 days. Either
parental strain or MRC5 parasites that were recovered after 12 days of growth in atovaquone
were grown in no or 3 μM atovaquone for either 5 days or 12 days and cultures were fixed and
stained to reveal plaques. Image of a representative plaque assay is shown. Despite growth in
the presence of atovaquone for 12 days, MRC5 parasites do not form plaques by five days indi-
cating that we have not selected for resistant parasites within the 12 day period used for the
assay shown in Fig 5.
(PDF)
S1 Table. Sequence of all primers used in this study.
(PDF)
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